Research has always been a key limiting market factor for cannabinoids, hemp-derived or otherwise.  There is a vast gap in knowledge stemming from so many decades of prohibition, making cannabis research during that era extremely onerous, and offering little political advantage for faculty or little profit for pharmaceutical companies. 

This isn’t to say that research was not done and drugs weren’t developed, because synthetic THC ‘Marinol’ for example was used for many years, though it hardly became commonplace.  Talk to palliative care patients or their families in years past, and it would be difficult to find ones that incorporated the synthetic ∆9-THC into their drug regimen. 

There is no data to determine how many patients self-medicated with MJ, and owing to the complex range of both cannabinoids and endocannabinoid binding characteristics, do not lend themselves to be easily researched.  The field of cannabinoid medicine is nascent and…